Importantly, the use of GLP-1 agonists was not regular in 54.5% of patients with obesity, and the primary goal of the treatment is to reduce weight rather than to prevent obesity-related comorbidities (72.4% versus 27.6%). This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.